The company offers cloud technology and AI services to accelerate treatments for ALS, with a focus on citizen-driven research and an open innovation platform for digital biomarkers to detect early diagnosis and prognosis of the disease. They collaborate with leading research institutions and have the largest study in ALS, with over 1,000 participants in less than 14 months.